
Phillip J Bergen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9662078/publications.pdf Version: 2024-02-01



DHILLID I REDCEN

#	Article	IF	CITATIONS
1	Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and <i>Enterobacterales</i> . Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0144621.	3.2	5
2	A polytherapy based approach to combat antimicrobial resistance using cubosomes. Nature Communications, 2022, 13, 343.	12.8	31
3	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220321.	3.2	4
4	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically III Patients in a Dynamic Infection Model. Antibiotics, 2022, 11, 101.	3.7	4
5	Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli. International Journal of Antimicrobial Agents, 2022, 59, 106505.	2.5	1
6	Coaching ward pharmacists in antimicrobial stewardship: A pilot study. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100131.	1.0	0
7	Pharmacokinetics and pharmacodynamics of peptide antibiotics. Advanced Drug Delivery Reviews, 2022, 183, 114171.	13.7	13
8	Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. British Journal of Clinical Pharmacology, 2021, 87, 3354-3358.	2.4	4
9	Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2021, 57, 106271.	2.5	15
10	Strategies to simplify complex medication regimens. Australian Journal of General Practice, 2021, 50, 43-48.	0.8	11
11	Evaluation of Meropenem iprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically III Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 109, 1104-1115.	4.7	16
12	Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing <i>Klebsiella pneumoniae</i> Is Predominately Driven by Chloramphenicol. ACS Infectious Diseases, 2021, 7, 1584-1595.	3.8	14
13	Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas aeruginosa and Minimize Biofilm Formation. Antibiotics, 2021, 10, 405.	3.7	7
14	Exploring the practice, confidence and educational needs of hospital pharmacists in reviewing antimicrobial prescribing: a cross-sectional, nationwide survey. BMC Medical Education, 2021, 21, 235.	2.4	4
15	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance, 2021, 26, 55-63.	2.2	7
16	Antimicrobial Peptides: An Update on Classifications and Databases. International Journal of Molecular Sciences, 2021, 22, 11691.	4.1	106
17	Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens. Frontiers in Pharmacology, 2021, 12, 785893.	3.5	7
18	A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. International Journal of Antimicrobial Agents, 2020, 55, 105833.	2.5	81

PHILLIP J BERGEN

#	Article	IF	CITATIONS
19	Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset). Data in Brief, 2020, 28, 104907.	1.0	2
20	Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates. Journal of Clinical Microbiology, 2020, 58, .	3.9	12
21	Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli. Frontiers in Microbiology, 2020, 11, 588658.	3.5	7
22	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
23	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
24	Transcriptomic responses of a New Delhi metallo-Î ² -lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. International Journal of Antimicrobial Agents, 2020, 56, 106061.	2.5	10
25	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically III Adult Patients: Clinician-Centered Design and Development Study. JMIR MHealth and UHealth, 2020, 8, e20525.	3.7	4
26	Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
27	Rational Combinations of Polymyxins with Other Antibiotics. Advances in Experimental Medicine and Biology, 2019, 1145, 251-288.	1.6	21
28	History, Chemistry and Antibacterial Spectrum. Advances in Experimental Medicine and Biology, 2019, 1145, 15-36.	1.6	22
29	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
30	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
31	Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. Journal of Antimicrobial Chemotherapy, 2018, 73, 1570-1578.	3.0	21
32	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
33	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2018, 91, 69-76.	1.8	4
34	Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study. Frontiers in Pharmacology, 2018, 9, 359.	3.5	14
35	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
36	Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of <i>Pseudomonas aeruginosa</i> , but do not suppress the emergence of fosfomycin resistance. Journal of Antimicrobial Chemotherapy, 2016, 71, 2218-2229.	3.0	32

Phillip J Bergen

#	Article	IF	CITATIONS
37	Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. International Journal of Antimicrobial Agents, 2016, 48, 592-597.	2.5	137
38	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	3.0	38
39	An "Unlikely―Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDEĆO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	3.8	80
40	Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. Journal of Antibiotics, 2016, 69, 415-421.	2.0	27
41	Safe disposal of prescribed medicines. Australian Prescriber, 2015, 38, 90-92.	1.0	14
42	Synergistic killing of NDM-producing MDR <i>Klebsiella pneumoniae</i> by two â€~old' antibiotics—polymyxin B and chloramphenicol. Journal of Antimicrobial Chemotherapy, 2015, 70, 2589-2597.	3.0	73
43	Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, 2015, 4, 391-415.	4.0	45
44	Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy, 2015, 35, 34-42.	2.6	52
45	Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i> : profiling the time course of synergistic killing and prevention of resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 1434-1442.	3.0	60
46	<i>In vitro</i> pharmacodynamics of fosfomycin against clinical isolates of <i>Pseudomonas aeruginosa</i> . Journal of Antimicrobial Chemotherapy, 2015, 70, 3042-3050.	3.0	72
47	The afterâ€life of drugs: a responsible care initiative for reducing their environmental impact. Medical Journal of Australia, 2014, 200, 83-83.	1.7	0
48	Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. Journal of Antimicrobial Chemotherapy, 2014, 69, 2434-2442.	3.0	59
49	Pharmacokinetic/Pharmacodynamic Investigation of Colistin against <i>Pseudomonas aeruginosa</i> Using an <i>In Vitro</i> Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 3783-3789.	3.2	150
50	Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2008, 61, 636-642.	3.0	119
51	Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 1953-1958.	3.2	325